ProQR director buys 150,000 company shares

ProQR Therapeutics N.V. director Bart Filius purchased 150,000 Ordinary Shares on July 17, 2026 at $1.7195 per share in a transaction described as a purchase in the open market or a private transaction.

Accepted by SEC EDGAR 07/21/2026 - 08:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ProQR Therapeutics N.V. director Bart Filius purchased 150,000 Ordinary Shares on July 17, 2026 at $1.7195 per share in a transaction described as a purchase in the open market or a private transaction. After this trade, he directly holds 300,000 Ordinary Shares of the company.

Insider Trade Summary

Net Buyer: 150,000 shares

Net Buy 1 txn

Insider Filius Bart

Role Director

Bought 150,000 shs ($258K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	150,000	$1.7195	$258K

Holdings After Transaction: Ordinary Shares — 300,000 shares (Direct)

Key Figures

Shares purchased: 150,000 Ordinary Shares Purchase price: $1.7195 per share Shares held after transaction: 300,000 Ordinary Shares +1 more

4 metrics

Shares purchased 150,000 Ordinary Shares Non-derivative purchase on July 17, 2026

Purchase price $1.7195 per share Price for the 150,000 Ordinary Shares acquired

Shares held after transaction 300,000 Ordinary Shares Director’s direct ownership following the purchase

Transaction date July 17, 2026 Date of the non-derivative share purchase

Key Terms

Ordinary Shares, open market or private transaction, direct ownership

3 terms

Ordinary Shares financial

"security_title: "Ordinary Shares" in the transaction record"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open market or private transaction financial

"transaction_code_description: "Purchase in open market or private transaction""

direct ownership financial

"ownership_type set to "direct" for the post-transaction holding"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ProQR Therapeutics (PRQR) report for Bart Filius?

Director Bart Filius purchased 150,000 Ordinary Shares of ProQR Therapeutics N.V. on July 17, 2026. The shares were bought at $1.7195 per share, and the transaction is described as an open market or private purchase.

At what price did the ProQR (PRQR) director buy the shares?

The director purchased the shares at an average price of $1.7195 per share. This price applies to the 150,000 Ordinary Shares acquired on July 17, 2026 in an open market or private transaction, as reported in the insider trading disclosure.

How many ProQR (PRQR) shares does Bart Filius own after this transaction?

Following the reported purchase, Bart Filius directly owns 300,000 Ordinary Shares of ProQR Therapeutics N.V. This figure reflects his holdings after acquiring 150,000 shares in the July 17, 2026 transaction at $1.7195 per share.

Was the ProQR (PRQR) insider purchase made under a Rule 10b5-1 trading plan?

The report indicates the Rule 10b5-1 checkbox is not marked as an affirmative plan. This means the 150,000-share purchase by director Bart Filius was not identified as executed pursuant to a pre-arranged 10b5-1 trading plan.

Is the ProQR (PRQR) director’s ownership classified as direct or indirect after the trade?

The ownership of 300,000 Ordinary Shares by director Bart Filius is reported as direct. The transaction data classifies the post-transaction holding with a direct ownership code, rather than through an indirect entity such as a trust or fund.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Filius Bart

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/17/2026		P		150,000	A	$1.7195	300,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)